Methylated BNIP3 gene in colorectal cancer prognosis

Oncology Letters

Volumn 1, Issue 5, 2010, Pages 865-872

  Shimizu, Sayaka ^a   Iida, Satoru ^a   Ishiguro, Megumi ^a   Uetake, Hiroyuki ^a   Ishikawa, Toshiaki ^a   Takagi, Yoko ^a   Kobayashi, Hirotoshi ^a   Higuchi, Tetsuro ^a   Enomoto, Masayuki ^a   Mogushi, Kaoru ^a   Mizushima, Hiroshi ^a   Tanaka, Hiroshi ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Colorectal cancer; Irinotecan; Methylation; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; PROTEIN BNIP3;

ADULT; APOPTOSIS; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROARRAY ANALYSIS; PROGNOSIS; TREATMENT RESPONSE; UPREGULATION;

EID: 77957584126     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000153     Document Type: Article

References (45)

1. Ricchi P, Zarrilli R, Di Palma A and Acquaviva AM: Nonsteroidal anti-inflammatory drugs in CRC: from prevention to therapy. Br J Cancer 88: 803-807, 2003.
2. Kobayashi H, Mochizuki H, Sugihara K, et al: Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer, a multicenter study. Surgery 141: 67-75, 2007.
3. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOL OL FFIRI followed by FOL OL FOX6 or the reverse sequence in advanced colorectal cancer: a randomized GE GE RCOR study. J Clin Oncol 22: 229-237, 2004.
4. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z Z, Sugihara K and Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidilate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 86-91, 2003.
5. Hengarter MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
6. Wyllie AH: Apoptosis. Br J Cancer 67: 205-208, 1993.
7. Compagni A and Chiristofori G: Recent advances in research on multistage tumorigenesis. Br J Cancer 83: 1-5, 2000.
8. Makin G and Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 11: S22-S26, 2001.
9. Fulda S and Debatin KM: Extrinsic vs. intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
10. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van E E ngeland M, Weijenberg MP, Herman JG and Baylin SB: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149, 2002.
11. Kondo Y and Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23: 29-39, 2004.
12. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
13. Teodoridis JM, Strathdee G and Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 7: 267-278, 2004.
14. Ishiguro M, Iida S, Uetake H, Morita S, Makino H, Kato K, Takagi Y, Enomoto M and Sugihara K: Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14: 1752-1762, 2007.
15. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K and Sugihara K: Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122: 603-608, 2008.
16. R, Development Core Team: R, A language and environment for statistical computing; R, Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org, 2006.
17. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis K J, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
18. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
19. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA NA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
20. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. New York, Wiley, 2002.
21. Therasse P, Arbuck SG, Eisenhauer EA EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
22. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE and Tannapfel A: Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 56: 1047-1053, 2007.
23. Murai M, Toyota M, Suzuki H, et al: Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 11: 1021-1027, 2005.
24. Hocker M, Schlenger K, Hockel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
25. Hocker M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
26. Zagzag D, Zhong H, Scalziti JM, Laughner E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618, 2000.
27. Blagosklonny MV: Antiangiogenic therapy and tumor progression. Cancer Cell 5: 13-17, 2004.
28. Manka D, Spicer Z and Millhorn DE: Bcl-2/Adenovirus E1B 19 kDa interacting protein-3 knockdown enables growth of breast cancer metastases in the lung, liver, and bone. Cancer Res 65: 11689-11693, 2005.
29. Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97: 9082-9087, 2001.
30. Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M and Ivashchenko Y: Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 8: 367-376, 2001.
31. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH AH and Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61: 6669-6673, 2001.
32. Bacon AL, Fox S, Turley H and Harris AL: Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene 26: 132-141, 2007.
33. De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E and Stokke T: Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 24: 1279-1288, 2004.
34. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA and Gibson SB: BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22: 4734-4744, 2003.
35. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R and Greenberg AH: BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454-5468, 2000.
36. Okami J, Simeone DM and Logsdon CD: Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 64: 5338-5346, 2004.
37. Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T and Imai K: Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumors. Br J Cancer 92: 1165-1172, 2005.
38. Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK: Nonproductive rearrangement of DNA Topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735, 1989.
39. Bras-Gonçalves RA, Rosty C, Laurent-Puig P, Soulié P, Dutrillaux B and Poupon MF: Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 82: 913-923, 2000.
40. Schmaltz C, Harrigan PH, Wells A and Fisher DE: Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 18: 2845-2854, 1998.
41. Oizumi S, Isobe H, Ogura S, Ishida T, Yamazaki K, Nishimura M, Kawakami Y and Dosaka-Akita H: Topoisomerase inhibitor-induced apoptosis accompanied by down regulation of Bcl-2 in human lung cancer cells. Anticancer Res 22: 4029-4037, 2002.
42. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET and Giavazzi R: Gene expression correlating with response to paclitaxel in ovarian carcinoma. Mol Cancer Ther 3: 111-121, 2004.
43. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNI NI P3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432, 2005.
44. Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S and Lemoine NR: Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11: 3094-3101, 2005.
45. Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC, Saxena S, Gietz RD and Greenberg AH: The E1B 19K/bcl-2-binding proteins Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med 186: 1975-1983, 1997.